Qube Research & Technologies Ltd - BLACK DIAMOND THERAPEUTICS I ownership

BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 59 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q4 2022. The put-call ratio across all filers is 2.84 and the average weighting 0.0%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of BLACK DIAMOND THERAPEUTICS I
ValueSharesWeighting
Q3 2023$8,375
-92.8%
2,918
-87.3%
0.00%
Q2 2023$115,665
+261.5%
22,904
+21.7%
0.00%
Q3 2022$32,000
-34.7%
18,813
-6.0%
0.00%
Q2 2022$49,000
-80.1%
20,012
-0.9%
0.00%
-100.0%
Q2 2021$246,00020,1890.00%
Other shareholders
BLACK DIAMOND THERAPEUTICS I shareholders Q4 2022
NameSharesValueWeighting ↓
NEA Management Company, LLC 3,449,845$8,487,0000.44%
Hawkeye Capital Management, LLC 243,009$598,0000.33%
Boxer Capital, LLC 2,014,858$4,957,0000.31%
Newtyn Management, LLC 520,000$1,279,0000.24%
Artal Group S.A. 1,646,517$4,050,0000.22%
DAFNA Capital Management LLC 313,600$771,0000.21%
RA Capital Management 2,589,904$6,371,0000.17%
Bellevue Group AG 4,717,113$11,605,0000.16%
MPM BioImpact LLC 239,888$590,0000.16%
K2 PRINCIPAL FUND, L.P. 507,652$1,249,0000.14%
View complete list of BLACK DIAMOND THERAPEUTICS I shareholders